Evidence map›Paper›PMID 39473263›Full record

ArticleJournal of neurochemistry2025

Circulating medium- and long-chain acylcarnitines are associated with plasma P-tau181 in cognitively normal older adults.

Tahmida Sharmin, Pratishtha Chatterjee, James D Doecke, Nicholas J Ashton, Kevin Huynh, Steve Pedrini, Hamid R Sohrabi, Benjamin Heng, Shaun Eslick, Henrik Zetterberg and 3 more

Abstract read
In one paragraph

Article in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. A seven-year longitudinal study of the Alzheimer's disease blood metabolome.medRxiv : the preprint server for health sciences · 2025
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Tahmida SharminMacquarie Medical School, Macquarie University, Macquarie Park, New South Wales, Australia.ORCID 0000-0001-5496-0670
Pratishtha ChatterjeeMacquarie Medical School, Macquarie University, Macquarie Park, New South Wales, Australia.ORCID 0000-0003-4877-1958
James D DoeckeAustralian eHealth Research Centre, CSIRO, Brisbane, Queensland, Australia.ORCID 0000-0003-2863-0293
Nicholas J AshtonDepartment of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.
Kevin HuynhMetabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Steve PedriniSchool of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.ORCID 0000-0002-6409-8022
Hamid R SohrabiMacquarie Medical School, Macquarie University, Macquarie Park, New South Wales, Australia.
Benjamin HengMacquarie Medical School, Macquarie University, Macquarie Park, New South Wales, Australia.
Shaun EslickMacquarie Medical School, Macquarie University, Macquarie Park, New South Wales, Australia.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0003-3930-4354
Kaj BlennowDepartment of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.
Manohar GargMacquarie Medical School, Macquarie University, Macquarie Park, New South Wales, Australia.
Ralph N MartinsMacquarie Medical School, Macquarie University, Macquarie Park, New South Wales, Australia.ORCID 0000-0002-4828-9363

Funding

European Union's Horizon Europe research and innovation programme 101053962MQ Research Seeding Grant, Macquarie University 2017-00915MQ Research Seeding Grant, Macquarie University 2018-02532MQ Research Seeding Grant, Macquarie University 201809-2016862MQ Research Seeding Grant, Macquarie University 681712Swedish Research Council 2019-02397
6 · The paper itself

Abstract

Alzheimer's disease (AD) pathogenesis involves dysregulation in diverse biochemical processes. Nevertheless, plasma tau phosphorylated at threonine 181 (P-tau181), a recognised AD biomarker, has been described to reflect early-stage cortical amyloid-β (Aβ) deposition in cognitively normal (CN) adults. Therefore, identifying changes in plasma metabolites associated with plasma P-tau181 at the pre-clinical stage may provide insights into underlying biochemical mechanisms to better understand initial AD pathogenesis. In the current study, plasma P-tau181, quantified via single molecule array (Simoa) technology, and plasma metabolites, quantified via targeted-mass spectrometry, were investigated for associations in CN older adults and upon stratification by positron emission tomography (PET)-Aβ load. In addition, the P-tau181-linked metabolites were evaluated for cognitive performance and neuroimaging markers of AD and the potential to distinguish between CN Aβ- and CN Aβ+ individuals. Significant positive associations of medium- and long-chain acylcarnitines (ACs) were observed with P-tau181 in the entire cohort, CN Aβ- and CN Aβ+, suggesting a link between initial Aβ pathology and fatty acid oxidation-mediated energy metabolism pathways. However, in CN Aβ-, additional linear associations of P-tau181 were observed with muscle metabolism and nitric oxide homeostasis-associated metabolites. Upon investigating the P-tau181-linked metabolites for cognitive performance, significant inverse correlations of the verbal and visual episodic memory and the global composite score were noted in CN Aβ+ with medium- and long-chain ACs, suggesting prognostic value of ACs accompanying weaker cognitive performance. While investigating neuroimaging markers, ACs had positive associations with PET-Aβ load and inverse associations with hippocampal volume in CN Aβ+, indicating connections of ACs with initial AD pathogenesis. Furthermore, based on receiver operating characteristics analysis, the associated ACs potentially classified PET-Aβ status in older adults. Therefore, plasma P-tau181-linked circulating ACs may serve as potential prognostic markers for initial AD pathogenesis in CN older adults. However, further cross-sectional and longitudinal research in highly characterised AD cohorts is needed to validate current findings.

Indexed as

CarnitineCognitiontau ProteinsAgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersFemaleHumansMaleMiddle AgedPhosphorylationPositron-Emission TomographyacylcarnitineAmyloid beta-PeptidesBiomarkersCarnitineMAPT protein, humantau ProteinsacylcarnitinesAlzheimer's diseasebiomarkerscognitively normal older adultsinitial pathogenesisP‐tau181

Identifiers

PMID39473263
PMCPMC11808462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.